基本信息
职称 教授、主任医师
职务 福州大学医工交叉研究院副院长福建省肿瘤医院副院长
研究方向 恶性肿瘤大数据筛查与临床诊疗、分子靶向药物研发
电子邮件 doctorsunyang@sina.com
个人简介
孙阳，男，博士,教授、主任医师、博士生导师。福建省高层次人才、福建省百千万人才工程省级人选、福建省卫生健康突出贡献中青年专家、美国梅奥医学中心访问学者。主要研究方向卵巢癌分子靶向药物研发、宫颈癌大数据筛查与临床诊疗。兼任中国抗癌协会子宫体肿瘤专委会副主任委员、福建省抗癌协会肿瘤内分泌专委会主任委员、福建省肿瘤生物治疗重点实验室常务副主任、福建省医学会妇科肿瘤学分会副主任委员、福建省抗癌协会妇科肿瘤专委会副主任委员以及AAGL、ESGO等多个国际学会会员等职务。近年专注于肿瘤大数据筛查与临床诊疗、小分子靶向药物研发等工作，重点开展肿瘤早筛与精准诊疗、肿瘤专病大数据系统设计、天然中药单体研发等研究，所带领的科研团队实验经验丰富、课题经费充足。
主持科研项目
1、鸡冠刺桐有效成分通过PXN/p110β/Beclin1通路调控细胞自噬抑制卵巢癌细胞侵袭转移的机制研究，2024.01-2027.12,主持，国家自然科学基金面上项目
2、自噬基因群影响宫颈癌放疗敏感性的机制研究和大数据转化探索，2023.07-2027.06,主持，福建省卫生健康中青年科研重大项目
3、天然中药单体及其衍生物调控自噬相关基因影响卵巢癌耐药细胞增殖的机制研究，2022.10-2025.10，主持，福建省科技创新联合资金重点项目
4、宝藿苷I调控自噬逆转卵巢癌顺铂耐药细胞株化疗敏感性的相关机制研究，2021.1-2023.12，主持，福建省医学创新课题
5、Per基因通过调节自噬相关基因启动子组蛋白修饰改变顺铂对耐药卵巢癌细胞死亡影响的相关研究，2020.11-2023.11，主持，福建省自然科学基金面上项目
6、吴茱萸生物碱诱导细胞自噬影响卵巢癌顺铂耐药细胞株增殖的相关机制研究，2019.1-2022.12，主持，国家自然科学基金面上项目
7、节律调节基因通过转录因子ATF4诱导自噬改变顺铂对宫颈癌细胞死亡影响的相关研究，2016.8-2019.7,主持，福建省自然科学基金面上项目
获奖经历
1、2021年，福建省科学技术进步奖三等奖（第一完成人）
2、2020年，福建省抗癌协会科技奖二等奖（第一完成人）
3、2016年，福建省科学技术进步奖二等奖（第一完成人）
4、2015年，福建省医学科技奖二等奖（第一完成人）
近3年发表的主要论文
1.Jiang S, Lin X, Wu Q, Zheng J, Cui Z, Cai X, Li Y, Zheng C,Sun Y. Transient Receptor Potential Channels' Genes Forecast Cervical Cancer Outcomes and Illuminate its Impact on Tumor Cells.Frontiers in genetics, 2024;15:1391842.
2.Cui Z, Li Y, Lin Y, Zheng C, Luo L, Hu D, Chen Y, Xiao Z,Sun Y. Lactylproteome analysis indicates histone H4K12 lactylation as a novel biomarker in triple-negative breast cancer. Front Endocrinol (Lausanne). 2024;15:1328679.
3.Cai X, Lin J, Liu L, Zheng J, Liu Q, Ji L,Sun Y. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer. BMC Cancer. 2024;24(1):515.
4.Ye X, Liu Q, Qin X, Ma Y, Sheng Q, Wu X, Chen S, Huang L,Sun Y. BCAR4 facilitates trastuzumab resistance and EMT in breast cancer via sponging miR-665 and interacting with YAP1. FASEB J. 2024;38(7):e23589.
5.Ji HZ, Liu B, Ren M, Li S, Zheng JF, Liu TY, Yu HH,Sun Y. The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer. Expert Rev Clin Immunol. 2024;20(5):559-569.
6.Zheng J, Jiang S, Lin X, Wang H, Liu L, Cai X andSun Y. Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer.BMC Women’s Health，2024,24(1):37.
7. Cai X, Li Y, Zheng J, Liu L, Jiao Z, Lin J, Jiang S, Lin X andSun Y.Modeling of senescence-related chemoresistance in ovarian cancer using data analysis and patient-derived organoids.Frontiers in Oncology, 2024,13:1291559. doi: 10.3389/fonc.2023.1291559
8.Lin X, Zheng J, Cai X, Liu L, Jiang S, Liu Q,Sun Y. Glycometabolism and lipid metabolism related genes predict the prognosis of endometrial carcinoma and their effects on tumor cells.BMC Cancer, 2024,24(1):571
9. Lin J, Lin J, Liu L, Xie N, Yu H, Deng S,Sun Y.A novel nomogram based on inflammation biomarkers for predicting radiation cystitis in patients with local advanced cervical cancer.Cancer Med,2024;13:e7245
10.Liu B, Liu Y, Liu W, Luo T, Chen W, Lin C, Ling L, Zhuo S,Sun Y. Label-free imaging diagnosis and collagen-optical evaluation of endometrioid adenocarcinoma with multiphoton microscopy.Journal of Biophotonics,2024;e202400177
11.Liu L, Lin J, Deng S, Yu H, Xie N,Sun Y. A novel nomogram and risk stratification for early metastasis in cervical cancer after radical radiotherapy. Cancer Med. 2023;12(24):21798-21806.
12.Jiang S, Zheng J, Cui Z, Li Y, Wu Q, Cai X, Zheng C,Sun Y. FBXO5 acts as a novel prognostic biomarker for patients with cervical cancer. Front Cell Dev Biol. 2023;11:1200197.
13.Zhou Y, Liu T, Wu Q, Wang H,Sun Y. Baohuoside I inhibits resistance to cisplatin in ovarian cancer cells by suppressing autophagy via downregulating HIF-1α/ATG5 axis. Mol Carcinog. 2023;62(10):1474-1486.
14.Jiang S, Cui Z, Zheng J, Wu Q, Yu H, You Y, Zheng C,Sun Y. Significance of Immunogenic Cell Death-Related Prognostic Gene Signature in Cervical Cancer Prognosis and Anti-Tumor Immunity. J Inflamm Res. 2023;16:2189-2207.
15.Chen Y, You Y, Wu Q, Wu J, Lin S,Sun Y, Cui Z. Performance of a PLK1-based immune risk model for prognosis and treatment response prediction in breast cancer. Cancer Med. 2023;12(9):11020-11039.
16. Xu Q, Wang J,Sun Y, et al. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. J Clin Oncol. 2022;40(16):1795-1805.
17.Chen Y, Cui Z, Wu Q, Wang H, Xia H,Sun Y. Long non-coding RNA HOXA11-AS knockout inhibits proliferation and overcomes drug resistance in ovarian cancer. Bioengineered. 2022;13(5):13893-13905.
18.Liu Q, Yang Y, Cheng M,Sun Y. The marine natural product, dicitrinone B, induces apoptosis through autophagy blockade in breast cancer. Int J Mol Med. 2022;50(4):130.
19.Zheng J, Cai X, Zhang Y,Sun Y. A comprehensive pan-cancer analysis of necroptosis molecules in four gynecologic cancers. BMC Cancer. 2022;22(1):1160.
20.Chen J,Sun Y, Chen L, et al. Prognostic factors and treatment of neuroendocrine tumors of the uterine cervix based on the FIGO 2018 staging system: a single-institution study of 172 patients. PeerJ. 2021;9:e11563.
21.Yang Y, Liu Q, Shi X, Zheng Q, Chen L,Sun Y. Advances in plant-derived natural products for antitumor immunotherapy. Arch Pharm Res. 2021;44(11):987-1011.
22.Ji H, Ren M, Liu T,Sun Y. Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment. Dis Markers. 2021;2021:5350232.
